Kura Oncology (NasdaqGS:KURA) Q3 2025 Earnings Call November 04, 2025 08:00 AM ET Speaker5Good day, everybody. My name is Danny, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology Third Quarter 2025 conference call. All lines have been placed on mute to prevent any background noises. After the speakers' remarks, there will be a question-and-answer session. If you would like to ask a question during this time and have joined via the webinar, please us ...

Kura Oncology (KURA) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -49.12%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.15 per share when it actually produced a loss of $0.75, delivering a surprise of -600%.Over the last four quarters, the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (Sta ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

– KOMET 017 Phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in frontline AML are accelerating; ziftomenib being investigated in settings representing more than 50% of AML patients – – Two oral presentations at 2025 ASH Annual Meeting on ziftomenib in combination with venetoclax / azacitidine chemotherapy in frontline and R/R NPM1-m AML – – Clinical data at ESMO 2025 Congress highlight promise of second strategic program – FTIs darlifarnib and tipifarnib sho ...

– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 – – KOMET 017 Phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in frontline AML are accelerating; ziftomenib being investigated in settings representing more than 50% of AML patients – – Two oral presentations at 2025 ASH Annual Meeting on ziftomenib in combination with venetoclax / azacitidine chemothera ...

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a $30 million milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first patient in the second of two KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. Kura previou ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use – SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced that results from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational menin inhibitor, will be featured in two oral p ...

人物背景 - 布伦丹拥有斯坦福大学有机合成博士学位（2009年）[1] - 其职业生涯始于默克公司（2009-2013年），之后在生物技术领域工作，包括初创公司Theravance和Aspira [1] - 作为首位员工和联合创始人，参与1200 Pharma公司从加州理工学院分拆出来，并获得八位数级别的重大投资 [1] - 目前仍是一名专注于市场趋势，特别是生物技术股票的投资人 [1] 分析师持仓披露 - 分析师在提及的公司中未持有任何股票、期权或类似衍生品头寸 [2] - 但可能在接下来72小时内通过购买股票或看涨期权等方式，建立KURA公司的多头头寸 [2] - 该文章为分析师个人所写，表达其个人观点，且除Seeking Alpha外未获得其他报酬 [2] - 分析师与文章提及的任何公司均无业务关系 [2]